This clinical trial is testing a small molecule called Anle138b to assess its potential to inhibit alpha-synuclein masses accumulating. In Parkinson’s, alpha-synuclein, which is abundant in nerve cells, begins clumping together (or aggregating) and it is believed that this process could be toxic.
This trial, it is hoped, will slow-down or halt the progression of Parkinson’s.
How helpful was this content?
/ 5. Vote count: